AbbVie (ABBV) News Today

AbbVie Inc. (NYSE: ABBV) shares appear to be moving higher on a mix of encouraging pipeline news and analyst support, though the stock is also being capped somewhat by a softer-than-expected 2026 earnings outlook.

• Positive Sentiment: The European Commission approved expanded use of Tepkinly (epcoritamab) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting. The approval is backed by Phase 3 data showing improved progression-free survival and strong response rates. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued confidence in upside potential. Article Title
• Positive Sentiment: Investor commentary also highlighted AbbVie as a high-yield dividend stock and a “low-stress” healthcare name, which can reinforce demand for the shares among income-focused investors. Article Title
• Neutral Sentiment: AbbVie’s Q2 2026 earnings guidance came in below analyst expectations, with EPS guidance of $3.57-$3.61 versus a consensus of $3.77. FY 2026 EPS guidance of $13.91-$14.11 also missed the Street’s estimate, which may temper some of the optimism from the pipeline news. Article Title
• Neutral Sentiment: Analyst previews ahead of AbbVie’s upcoming Q2 results noted that investors are watching Skyrizi and Rinvoq to offset Humira’s decline, keeping attention on whether newer immunology products can sustain growth. Article Title

Overall, ABBV looks supported by fresh international approval for Tepkinly and bullish analyst commentary, while the below-consensus guidance is the main offsetting factor.